½ÃÀ庸°í¼­
»óǰÄÚµå
1671873

°â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°, ¿¬·ÉÃþº°, Åõ¿© °æ·Îº°, ÃÖÁ¾»ç¿ëÀÚº°, À¯Åë ä³Îº°, Áö¿ªº°

Sickle Cell Disease Treatment Market, By Treatment Type, By Age Group, By Route of Administration, By End User, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀåÀº 2025³â¿¡ 32¾ï ´Þ·¯, 2032³â¿¡´Â 88¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 15.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 32¾ï ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 15.6% 2032³â °¡Ä¡ ¿¹Ãø 88¾ï 1,000¸¸ ´Þ·¯
±×¸². °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2025³â
Sickle Cell Disease Treatment Market-IMG1

°â»ó ÀûÇ÷±¸ ÁúȯÀº ºñÁ¤»óÀûÀÎ ÀûÇ÷±¸¸¦ À¯¹ßÇÏ´Â À¯Àü¼º Ç÷¾× ÁúȯÀÔ´Ï´Ù. ü³» Á¶Á÷°ú Àå±â¿¡ »ê¼Ò °ø±Þ¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÀÌ ÁúȯÀº Àü ¼¼°è, ƯÈ÷ »çÇ϶ó À̳² ¾ÆÇÁ¸®Ä«, Áßµ¿, Àεµ ¾Æ´ë·ú, ÁöÁßÇØ Áö¿ª, Áß³²¹Ì µîÁö¿¡¼­ À¯ÇàÇϰí ÀÖ½À´Ï´Ù. Áø´Ü ¹× ¹ß°ß·ü Áõ°¡¿Í ´õºÒ¾î °í±Þ Ä¡·á ¿É¼ÇÀÇ °¡¿ë¼º¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÇâÈÄ ¸î ³âµ¿¾È ½ÃÀåÀº À¯¸®ÇÑ ±âȸ¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »õ·Î¿î ¾à¹° ¿ä¹ý ¹× À¯ÀüÀÚ Ä¡·á ±â¹Ý Ä¡·á Á¢±Ù¹ýÀÇ °³¹ßµµ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

½Å¾à ¹× ÇâÈÄ ÆÄÀÌÇÁ¶óÀÎ Èĺ¸¹°Áú °³¹ß¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸ Ȱµ¿ÀÌ È°¹ßÇØÁö¸é¼­ ¼¼°è °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ½ÅÈï±¹ÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í À¯¸®ÇÑ »óȯ Á¤Ã¥Àº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °ñ¼ö À̽İú °°Àº ±Ùº»ÀûÀÎ Ä¡·á¹ýÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÷´Ü Ä¡·á Á¢±Ù¹ý¿¡ µû¸¥ ³ôÀº ºñ¿ë°ú Àú°³¹ß Áö¿ª¿¡¼­ÀÇ ³·Àº ÀÎÁöµµ´Â ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ Ä¡·á ±â¹Ý Ä¡·á¹ýÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ½ÃÀå Âü¿©Àڵ鿡°Ô Å« ±âȸ°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àú·ÅÇÑ °¡°ÝÀÇ Àç»ý Ä¡·á ¿É¼ÇÀÇ °³¹ßÀº °¡±î¿î ¹Ì·¡¿¡ »õ·Î¿î ±æÀ» ¿­ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.

¼¼°è °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀ» ±â¾÷ ¼Ò°³, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ÁÖ¿ä ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.

½ÃÀå ÁÖ¿ä ±â¾÷À¸·Î´Â Novartis AG, Emmaus Medical Inc., Agios Pharmaceuticals Inc, Bluebird Bio, Pfizer Inc. Corporation, GSK(GlaxoSmithKline), Sanofi S.A., Merck &Co., Amgen Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°è °â»ó ÀûÇ÷±¸Áõ Ä¡·á ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ °ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
  • ±âȸ
  • ¿µÇ⠺м®
  • ÁÖ¿ä ¹ßÀü
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° ¹ß¸Å/½ÂÀÎ
  • PEST ºÐ¼®
  • PORTER ºÐ¼®
  • ÀμöÇÕº´(M&A) ½Ã³ª¸®¿À
  • ¾÷°è µ¿Çâ

Á¦4Àå ¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå, Ä¡·á À¯Çüº°, 2020³â-2032³â

  • ¼öÇ÷
  • °ñ¼ö À̽Ä
  • ¾à¹° ¿ä¹ý
  • ÇÏÀ̵å·Ï½Ã¿ì·¹¾Æ ¿ä¹ý
  • Oxbryta
  • Adakveo
  • ÅëÁõ °ü¸®¾à
  • ±âŸ

Á¦5Àå ¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå, ¿¬·É ±×·ìº°, 2020³â-2032³â

  • ¼ºÀÎ
  • ¼Ò¾Æ
  • ³ëÀÎ

Á¦6Àå ¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå, Åõ¿© °æ·Îº°, 2020³â-2032³â

  • °æ±¸
  • ºñ°æ±¸

Á¦7Àå ¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020³â-2032³â

  • º´¿ø
  • Àü¹® Ŭ¸®´Ð
  • °¡Á¤Ä¡·á ȯ°æ
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå, À¯Åë ä³Îº°, 2020³â-2032³â

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦9Àå ¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå, Áö¿ªº°, 2020³â-2032³â

  • ºÏ¹Ì
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • Novartis AG
  • Emmaus Medical Inc.
  • Agios Pharmaceuticals Inc.
  • Bluebird Bio
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • GSK(GlaxoSmithKline)
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Chugai Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Company, Limited

Á¦11Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×

  • Wheel of Fortune
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
  • COM(Coherent Opportunity Map)

Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

  • Âü°í ¹®Çå
  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç¿¡ ´ëÇØ
LSH 25.04.08

The Global Sickle Cell Disease Treatment Market is estimated to be valued at USD 3.20 Bn in 2025 and is expected to reach USD 8.81 Bn by 2032 exhibiting a compound annual growth rate (CAGR) of 15.6% from 2025 to 2032

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 3.20 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 15.60% 2032 Value Projection: USD 8.81 Bn
Figure. Sickle Cell Disease Treatment Market Share (%), By Region, 2025
Sickle Cell Disease Treatment Market - IMG1

Sickle cell disease is a genetic blood disorder causing abnormal red blood cells. It affects the oxygen supply to tissues and organs in the body. This disorder is prevalent across worldwide, especially in Sub-Saharan Africa, the Middle East, Indian subcontinent, Mediterranean regions, and South and Central America. With growing diagnostic and detection rates, coupled with rising awareness regarding availability of advanced treatment options, the market is projected to showcase lucrative opportunities over the coming years. The development of new drug therapies and gene-therapy based treatment approaches are also fueling the market expansion.

Market Dynamics:

Increasing research activities focusing on developing novel drugs and upcoming pipeline candidates are acting as a key growth driver for global sickle cell disease treatment market. Rising healthcare expenditures in emerging nations and favorable reimbursement policies are further supporting the market growth. Growing adoption of curative therapies such as bone marrow transplantation is also boosting the market. However, high costs associated with advanced treatment approaches and lack of awareness in underdeveloped regions are restraining the market growth. Rising adoption of gene-therapy based treatments presents significant opportunities for market players. Development of affordable regenerative treatment options also holds potential to create new avenues in the near future.

Key Features of the Study:

This report provides in-depth analysis of the global sickle cell disease treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global sickle cell disease treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Novartis AG, Emmaus Medical Inc., Agios Pharmaceuticals Inc., Bluebird Bio, Pfizer Inc., Bristol-Myers Squibb Company, Celgene Corporation, GSK (GlaxoSmithKline), Sanofi S.A., Merck & Co., Inc., Amgen Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Company, Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global sickle cell disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sickle cell disease treatment market

Market Segmentation

  • By Treatment Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Blood Transfusion
    • Bone Marrow Transplant
    • Pharmacotherapy
    • Hydroxyurea Therapy
    • Oxbryta
    • Adakveo
    • Pain Management Drugs
    • Others
  • By Age Group Insights (Revenue, USD Bn, 2020 - 2032)
    • Adults
    • Pediatric
    • Geriatric
  • By Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
    • Oral
    • Parenteral
  • By End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospitals
    • Specialty Clinics
    • Homecare Settings
    • Others
  • By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Novartis AG
    • Emmaus Medical Inc.
    • Agios Pharmaceuticals Inc.
    • Bluebird Bio
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • GSK (GlaxoSmithKline)
    • Sanofi S.A.
    • Merck & Co., Inc.
    • Amgen Inc.
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd.
    • Chugai Pharmaceutical Co., Ltd.
    • Daiichi Sankyo Company, Limited

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Sickle Cell Disease Treatment Market, By Treatment Type
    • Global Sickle Cell Disease Treatment Market, By Age Group
    • Global Sickle Cell Disease Treatment Market, By Route of Administration
    • Global Sickle Cell Disease Treatment Market, By End User
    • Global Sickle Cell Disease Treatment Market, By Distribution Channel
    • Global Sickle Cell Disease Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Driver
    • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Sickle Cell Disease Treatment Market, By Treatment Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Blood Transfusion
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Bone Marrow Transplant
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Pharmacotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hydroxyurea Therapy
  • Oxbryta
  • Adakveo
  • Pain Management Drugs
  • Others

5. Global Sickle Cell Disease Treatment Market, By Age Group, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Adults
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Sickle Cell Disease Treatment Market, By Route of Administration, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Parentral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Sickle Cell Disease Treatment Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Homecare Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Sickle Cell Disease Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Sickle Cell Disease Treatment Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

10. Competitive Landscape

  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Emmaus Medical Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Agios Pharmaceuticals Inc.
  • Bluebird Bio
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • GSK (GlaxoSmithKline)
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Chugai Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Company, Limited

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦